162 related articles for article (PubMed ID: 9446350)
1. [Antigens CA-50 and CA-242 in digestive tract and thyroid neoplasms].
Pomorski L; Pasieka Z; Kołomecki K; Czyz W; Kołodziejczyk M; Wróbel B
Wiad Lek; 1997; 50 Suppl 1 Pt 1():18-20. PubMed ID: 9446350
[TBL] [Abstract][Full Text] [Related]
2. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of serum TAC-41 in various digestive cancers].
Sato S; Yamanaka T; Kimura K
Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
Chen SB
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
[TBL] [Abstract][Full Text] [Related]
5. CA 50 and CA 19-9 antigen expression in normal, hyperplastic, and neoplastic thyroid tissue.
Vierbuchen M; Schröder S; Uhlenbruck G; Ortmann M; Fischer R
Lab Invest; 1989 May; 60(5):726-32. PubMed ID: 2716285
[TBL] [Abstract][Full Text] [Related]
6. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
Olsson NO; Crimet-Montange D; Martin F
Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
[TBL] [Abstract][Full Text] [Related]
8. [The differential diagnosis of thyroid cancer using radioimmunologic analysis].
Ametov AS; Voronetskiĭ IB; Ol'shanskiĭ VO; Toritsyna LK; Larina IM
Med Radiol (Mosk); 1990 Feb; 35(2):11-4. PubMed ID: 2314197
[TBL] [Abstract][Full Text] [Related]
9. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
Anzai K; Kurihara M; Izumi T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
[TBL] [Abstract][Full Text] [Related]
10. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
12. [Serum level of tumor markers (antigen Ca 19-9, CEA, ferritin) in digestive tumors. Their diagnostic usefulness].
Jovin G; Stănel I; Popovici I; Oproiu A
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(3):223-9. PubMed ID: 2904162
[No Abstract] [Full Text] [Related]
13. [Usefulness of the determination of CA 19-9 in the follow-up of patients with gastroenteric neoplasms in comparison to CEA].
Pecchio F; Piantino P; Oliaro A; Rapellino M; Ricci E; Aimo G; Obert R
Minerva Med; 1986 Nov; 77(42-43):1973-81. PubMed ID: 3464850
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
[TBL] [Abstract][Full Text] [Related]
15. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
16. Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer.
Hamy A; Mirallié E; Bennouna J; Resche I; Drefty C; Johnstone M; Visset J
Eur J Surg Oncol; 2004 Aug; 30(6):681-5. PubMed ID: 15256244
[TBL] [Abstract][Full Text] [Related]
17. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
[TBL] [Abstract][Full Text] [Related]
18. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of the efficacy of the combined determination of serum markers CEA, CA 19.9, CA 72.4 as indexes of gastro-intestinal tract neoplasms].
Marchei P; Cifaldi L; De Benedetto A; Santini D; Manna A; Trasatti L; Marchei GG; Reale MG
G Ital Oncol; 1990; 10(4):121-4. PubMed ID: 2093080
[TBL] [Abstract][Full Text] [Related]
20. CEA and CA 19-9 as prognostic indexes in colorectal cancer.
Forones NM; Tanaka M
Hepatogastroenterology; 1999; 46(26):905-8. PubMed ID: 10370636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]